Urgent Updates | October 12

Paxlovid Weaker Against Current COVID-19 Variants

A real-world study published in JAMA found that Pfizer’s COVID-19 antiviral Paxlovid is now less effective at preventing hospitalization or death in high-risk patients as compared to earlier studies. But when looking at death alone, the antiviral was still highly effective.  In preventing death alone, Paxlovid was about 84% effective compared to no treatment and Lagevrio was about 77% effective, the study said.

Full Access: Medscape


The Medical Management of Gastroesophageal Reflux Disease: A Narrative Review

A systematic search of the databases of PubMed/MEDLINE, Embase, and Cochrane Library was performed for articles on the medical management of GERD. Although pharmacological therapy has been associated with potential adverse events, further research is needed to determine if this association exists. For this reason, lifestyle modifications should be considered first-line, while pharmacologic therapy can be considered in patients in whom lifestyle modifications have proven to be ineffective in controlling their symptoms or cannot institute them. Naturally, extra-esophageal causes for GERD-like symptoms must be considered on suspected high-risk patients and excluded before considering treatment for GERD.  Full Access: Sage Journals


Long-term symptom profiles after COVID-19 vs other acute respiratory infections: an analysis of data from the COVIDENCE UK study

Some people may experience long-term symptoms — or ‘long colds’— after acute respiratory infections (ARI) that test negative for COVID-19. Researchers included 10,171 participants (1311 [12.9%] with SARS-CoV-2 infection, 472 [4.6%] with non-COVID-19 ARI) in this prospected, population-based study. Both types of infection were associated with increased prevalence/severity of most symptoms and decreased, and health-related quality of life (HRQoL) compared with no infection. Full Access: The Lancet


This Symptom Signals UTI in 83% of Cases

Researchers found that dyspareunia is a major indicator of urinary tract infections. The symptom is especially accurate at identifying UTIs in no menopausal women. Among all 5500 patients, 83% of those who had UTIs experienced dyspareunia. 80% of women of reproductive age with dyspareunia had an undiagnosed UTI. During the perimenopausal and postmenopausal years, dyspareunia was more often associated with genitourinary syndrome than UTIs. 94% of women with UTI-associated dyspareunia responded positively to antibiotics. Full Access: Medscape